GO:0048632 negative regulation of skeletal muscle tissue growth: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048632 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of skeletal muscle growth.
• Myostatin (MSTN), a TGF-beta superfamily member, is the archetypal negative regulator of skeletal muscle growth; its loss causes dramatic muscle hyperplasia and hypertrophy in mammals.
• Negative regulation of muscle growth is critical for maintaining muscle mass balance and is dysregulated in cancer cachexia, sarcopenia, and muscular dystrophies.
• The process is controlled by a network of secreted ligands, receptors, intracellular signaling cascades (SMAD2/3, NF-kB, FoxO), and microRNAs.
• Experimental models for studying this term include MSTN knockout mice, myostatin inhibition, and CRISPR-engineered cell and animal models.
• Understanding negative regulation of skeletal muscle growth informs therapeutic strategies for muscle-wasting conditions and metabolic health.
Description
Skeletal muscle is a highly plastic tissue whose mass is determined by the balance between anabolic and catabolic processes. The Gene Ontology term GO:0048632, negative regulation of skeletal muscle tissue growth, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of skeletal muscle growth. This term is fundamental for researchers studying muscle homeostasis, regeneration, and atrophy, as it defines the molecular brakes that limit excessive muscle enlargement. Dysregulation of these brakes contributes to pathological muscle loss in cancer cachexia, sarcopenia, and inherited myopathies. The most well-characterized negative regulator is myostatin (MSTN), a TGF-beta superfamily ligand that acts as a chalone to restrict muscle fiber size and number. Since its discovery, myostatin has become a paradigm for understanding how secreted factors can dominantly suppress muscle growth, and it remains a major therapeutic target for muscle-wasting diseases. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0048632, covering its definition, mechanisms, key genes, disease relevance, and experimental approaches.
negative regulation of skeletal muscle tissue growth At A Glance
| GO ID | GO:0048632 |
|---|---|
| GO term | negative regulation of skeletal muscle tissue growth |
| Ontology | biological_process |
| Synonym | down regulation of skeletal muscle growth, down-regulation of skeletal muscle growth, downregulation of skeletal muscle growth, inhibition of skeletal muscle growth |
| Major function | Suppression of skeletal muscle growth through inhibition of myogenesis, protein synthesis, and hypertrophy signaling |
| Key regulators | MSTN, ACVR2B, SMAD2/3, FOXO, NF-kB, myostatin propeptide, follistatin |
| Related processes | Muscle atrophy, protein degradation, TGF-beta signaling, myostatin signaling |
| Disease relevance | Cancer cachexia, sarcopenia, muscular dystrophies, disuse atrophy |
What Is GO:0048632?
GO:0048632 is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle growth. In other words, it includes all molecular and cellular events that put the brakes on the increase in skeletal muscle mass, whether by inhibiting myoblast proliferation, limiting protein synthesis, promoting protein degradation, or restraining fiber hypertrophy. This term is a biological process and is distinct from positive regulation of skeletal muscle growth (GO:0048633).
Why Is negative regulation of skeletal muscle tissue growth Important in Cell Biology?
GO:0048632 is important because it defines the molecular mechanisms that prevent uncontrolled muscle growth and maintain muscle mass homeostasis. In healthy individuals, negative regulation of muscle growth ensures that muscle size is appropriate for mechanical load and metabolic demand. When these mechanisms are pathologically activated, they drive muscle wasting, a hallmark of cancer cachexia, chronic disease, and aging. Conversely, therapeutic inhibition of negative regulators such as myostatin can increase muscle mass and strength, offering potential treatments for sarcopenia and muscular dystrophies. Thus, understanding this GO term is essential for both basic muscle biology and translational medicine.
• Maintains muscle mass balance by preventing excessive hypertrophy under normal conditions.
• Dysregulated in cancer cachexia, where systemic inflammation and tumor-derived factors activate muscle catabolism.
• Contributes to age-related sarcopenia and loss of muscle function.
• Myostatin, a key negative regulator, is a validated target for muscle-wasting therapies.
• Involved in metabolic health, as muscle mass influences glucose disposal and energy expenditure.
• Provides a framework for understanding muscle regeneration and repair after injury.
• Guides development of CRISPR-based models to dissect gene function in muscle growth.
• Relevant to livestock breeding, where natural mutations in MSTN increase muscle mass.
• Helps explain sexual dimorphism in muscle mass and response to exercise.
• Offers insights into the interplay between protein synthesis and degradation pathways.
What Happens During negative regulation of skeletal muscle tissue growth?
Initiation by secreted ligands
In simple terms: The process often starts when signaling molecules like myostatin are released and bind to receptors on muscle cells.
Negative regulation of skeletal muscle growth is frequently initiated by secreted TGF-beta superfamily ligands, most notably myostatin (MSTN). Myostatin is produced as a precursor protein that is cleaved to generate an N-terminal propeptide and a C-terminal mature dimer. The mature myostatin dimer binds to activin type II receptors (ACVR2A/ACVR2B) on the surface of muscle cells, triggering intracellular signaling. This ligand-receptor interaction is the first step in a cascade that ultimately suppresses muscle growth.
Intracellular signaling cascades
In simple terms: Once the signal reaches inside the cell, it activates proteins that tell the nucleus to stop building muscle.
Upon ligand binding, ACVR2B phosphorylates and activates type I receptors (ALK4/5), which in turn phosphorylate SMAD2 and SMAD3. Phosphorylated SMAD2/3 form complexes with SMAD4 and translocate to the nucleus, where they regulate transcription of target genes that inhibit myogenesis and promote atrophy. In parallel, myostatin can activate non-SMAD pathways, including the MAPK/ERK and NF-kB pathways, further reinforcing the negative regulation of muscle growth.
Transcriptional reprogramming
In simple terms: The cell changes which genes are turned on or off, leading to less muscle protein and more breakdown.
SMAD2/3 complexes in the nucleus suppress the expression of myogenic regulatory factors such as MyoD and myogenin, thereby inhibiting myoblast differentiation and fusion. They also upregulate the expression of E3 ubiquitin ligases, including atrogin-1 (FBXO32) and MuRF1 (TRIM63), which target muscle proteins for degradation via the ubiquitin-proteasome system. Additionally, myostatin signaling inhibits the Akt/mTOR pathway, reducing protein synthesis. The net effect is a decrease in muscle fiber size and number.
Cellular outcomes: atrophy and reduced hypertrophy
In simple terms: The final result is smaller or fewer muscle fibers, meaning less muscle mass.
The integrated outcome of these signaling events is a reduction in skeletal muscle growth. This can manifest as atrophy of existing fibers, impaired regeneration after injury, or blunted hypertrophic response to exercise or anabolic stimuli. In conditions such as cancer cachexia, chronic activation of these pathways leads to progressive muscle wasting. Conversely, genetic deletion of myostatin results in a dramatic increase in muscle mass, underscoring the potent role of this negative regulator.
Key Genes Involved in GO:0048632 negative regulation of skeletal muscle tissue growth
The following genes and proteins are central to the negative regulation of skeletal muscle tissue growth, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSTN | Secreted TGF-beta ligand that inhibits muscle growth | Primary negative regulator; knockout causes hypermuscularity |
| ACVR2B | Activin receptor type IIB; binds myostatin and activin | Mediates myostatin signaling; target for inhibition |
| ACVR2A | Activin receptor type IIA; alternative receptor for myostatin | Compensatory receptor in myostatin signaling |
| SMAD2 | Intracellular signal transducer downstream of TGF-beta | Phosphorylated by type I receptors; regulates transcription |
| SMAD3 | Intracellular signal transducer downstream of TGF-beta | Forms complexes with SMAD4 to inhibit myogenesis |
| SMAD4 | Common mediator SMAD; partners with SMAD2/3 | Essential for nuclear translocation and transcriptional regulation |
| FOXO1 | Forkhead transcription factor; promotes atrophy | Upregulates atrogin-1 and MuRF1; inhibited by Akt |
| FOXO3 | Forkhead transcription factor; promotes atrophy | Induces autophagy and ubiquitin-proteasome genes |
| FBXO32 | E3 ubiquitin ligase (atrogin-1); targets muscle proteins | Key mediator of protein degradation in atrophy |
| TRIM63 | E3 ubiquitin ligase (MuRF1); targets sarcomeric proteins | Critical for muscle atrophy; knockout preserves muscle mass |
| NFKB1 | Transcription factor; promotes inflammation and atrophy | Activated by myostatin; induces MuRF1 |
| FST | Follistatin; binds and inhibits myostatin | Endogenous antagonist; overexpression increases muscle mass |
| MSTN propeptide | N-terminal fragment of myostatin precursor | Inhibits myostatin activity; potential therapeutic |
| IGF1 | Insulin-like growth factor 1; promotes muscle growth | Opposes negative regulation via Akt/mTOR |
| AKT1 | Serine/threonine kinase; promotes protein synthesis | Inhibited by myostatin; central node in hypertrophy |
| MTOR | Kinase; master regulator of protein synthesis | Suppressed by myostatin; target of rapamycin |
| MIR133A | MicroRNA; regulates myoblast proliferation and differentiation | Modulates myostatin signaling; potential therapeutic |
How Is negative regulation of skeletal muscle tissue growth Regulated?
The negative regulation of skeletal muscle tissue growth is itself tightly regulated by multiple feedback loops and interacting proteins. Myostatin activity is controlled extracellularly by binding proteins such as follistatin, which sequesters myostatin and prevents receptor activation. The myostatin propeptide also remains non-covalently bound to the mature dimer, keeping it latent until further cleavage by BMP-1/TLD proteases. Intracellularly, the SMAD2/3 pathway is modulated by inhibitory SMADs (SMAD6/7) and by crosstalk with other signaling cascades, including the IGF-1/Akt/mTOR pathway, which promotes muscle growth and opposes myostatin action. Additionally, microRNAs such as miR-133a can fine-tune myostatin receptor expression and downstream signaling. In pathological states, inflammatory cytokines like TNF-alpha and IL-6 can synergize with myostatin to amplify muscle catabolism.
negative regulation of skeletal muscle tissue growth and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MSTN | Cancer cachexia, sarcopenia, muscular dystrophy | MSTN knockout mouse; myostatin inhibition in cachexia models |
| ACVR2B | Muscle wasting; myostatin signaling | ACVR2B dominant-negative knock-in mouse; soluble ACVR2B decoy |
| FBXO32 | Muscle atrophy; protein degradation | FBXO32 knockout mouse; CRISPR KO in C2C12 myotubes |
| TRIM63 | Muscle atrophy; sarcomeric protein degradation | TRIM63 knockout mouse; overexpression in muscle cells |
| FOXO3 | Atrophy, autophagy | FOXO3 knockout or constitutively active mutants in muscle |
Cancer cachexia
Cancer cachexia is a multifactorial syndrome characterized by ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support. Negative regulation of skeletal muscle growth is pathologically activated in cachexia through tumor-derived factors and systemic inflammation, leading to increased myostatin expression, SMAD2/3 activation, and upregulation of ubiquitin-proteasome genes. This results in accelerated muscle protein degradation and suppressed protein synthesis, contributing to progressive functional impairment and poor prognosis.
Sarcopenia and aging
Sarcopenia, the age-related loss of muscle mass and strength, involves an imbalance between anabolic and catabolic signals. With aging, negative regulators of muscle growth such as myostatin and inflammatory cytokines become more active, while anabolic stimuli like IGF-1 decline. This shift promotes muscle atrophy and impairs regeneration after injury. Therapeutic strategies aimed at inhibiting myostatin or enhancing anabolic signaling are being explored to preserve muscle mass in older adults.
Muscular dystrophies
In Duchenne muscular dystrophy and related disorders, chronic muscle degeneration and regeneration lead to fibrosis and failed regeneration. Myostatin is upregulated in dystrophic muscle and contributes to impaired regeneration and increased fibrosis. Preclinical studies have shown that inhibiting myostatin signaling can increase muscle mass and improve function in dystrophic animal models, although clinical translation remains challenging.
Disuse atrophy
Immobilization, bed rest, and spaceflight cause rapid muscle loss through activation of negative regulators. Reduced mechanical loading leads to decreased IGF-1/Akt/mTOR signaling and increased expression of myostatin, atrogin-1, and MuRF1. This results in accelerated protein degradation and reduced protein synthesis, highlighting the importance of negative regulation in disuse conditions.
From negative regulation of skeletal muscle tissue growth-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase muscle mass? | Knockout mouse (e.g., MSTN KO) or CRISPR KO in C2C12 myoblasts |
| Does a specific point mutation in MSTN alter its activity? | Point-mutation knock-in mouse or cell line expressing mutant MSTN |
| Does a disease-associated variant affect myostatin signaling? | Knock-in of the variant in HEK293 or muscle cells; reporter assays |
| Where and when is a negative regulator expressed? | Tagged knock-in (e.g., GFP or HA) in mouse or human iPSC-derived muscle |
| Does overexpression of an antagonist block myostatin? | Overexpression of follistatin or propeptide in muscle cells or mouse |
| Can CRISPR screening identify novel negative regulators? | Genome-wide CRISPR knockout library in C2C12 myoblasts followed by differentiation assay |
How to Study the negative regulation of skeletal muscle tissue growth Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify differentially expressed genes in KO vs WT muscle |
| Phosphoproteomics | Phosphorylation status of signaling proteins | Measure SMAD2/3 and Akt/mTOR activity |
| Western blot | Protein abundance and phosphorylation | Validate myostatin signaling in cell lines |
| Immunofluorescence | Localization and fiber size | Assess myotube diameter and fusion index |
| CRISPR knockout screen | Gene function on a genome-wide scale | Discover novel negative regulators of muscle growth |
| Reporter assays | Transcriptional activity of SMAD or NF-kB | Test myostatin inhibitors in vitro |
| Muscle strength testing | Functional muscle performance | Evaluate therapeutic interventions in mouse models |
| Histology (H&E, Masson) | Fiber morphology and fibrosis | Assess muscle pathology in dystrophy models |
Transcriptomic profiling (RNA-seq)
RNA sequencing can quantify changes in gene expression associated with negative regulation of muscle growth. For example, comparing wild-type and MSTN-knockout muscle reveals upregulation of myogenic factors and downregulation of atrophy genes. RNA-seq is also used to identify novel transcripts and non-coding RNAs involved in this process.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based proteomics can measure protein abundance and post-translational modifications in muscle tissue. Phosphoproteomics is particularly useful for tracking SMAD2/3 phosphorylation and Akt/mTOR activity, which are central to myostatin signaling. These methods provide a systems-level view of the signaling network.
Functional assays for muscle growth
In vitro assays using C2C12 myoblasts measure proliferation, differentiation, and myotube size. Myostatin treatment inhibits differentiation and reduces myotube diameter, while knockdown of negative regulators enhances differentiation. In vivo, muscle mass and fiber cross-sectional area are quantified after genetic manipulation or drug treatment.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens in muscle cells can identify genes that negatively regulate muscle growth. For instance, a screen for regulators of myoblast differentiation could uncover novel components of the myostatin pathway. These screens are powerful for discovering new therapeutic targets.
How CRISPR Can Be Used to Study GO:0048632 negative regulation of skeletal muscle tissue growth
Knockout
CRISPR knockout of negative regulators such as MSTN, ACVR2B, or FBXO32 can be used to study their role in muscle growth. For example, MSTN knockout mice generated by CRISPR exhibit increased muscle mass, confirming its function as a negative regulator. In cell culture, knockout of these genes can enhance myoblast differentiation and myotube hypertrophy, providing a platform for drug testing.
Point Mutation
Point mutations can be introduced to model naturally occurring variants or to dissect functional domains. For instance, mutations in the myostatin propeptide cleavage site can prevent processing and alter activity. CRISPR base editing or homology-directed repair can create such point mutations in muscle cell lines or mice to study their effects on muscle growth.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) or disease-associated variants allows precise tracking of gene expression and function. A tagged MSTN knock-in mouse can reveal spatiotemporal expression patterns during development and regeneration. Knock-in of human disease variants into mouse models can help validate their pathogenicity in muscle wasting conditions.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression constructs can drive high-level expression of negative regulators or their antagonists. Overexpressing follistatin, a myostatin antagonist, increases muscle mass in mice. Conversely, overexpressing myostatin or its receptors can induce atrophy, providing a model for cachexia research.
How EDITGENE Supports negative regulation of skeletal muscle tissue growth Research
Researchers studying negative regulation of skeletal muscle tissue growth-related genes often need to determine whether a candidate gene is causally involved in muscle mass regulation. This requires precise genetic manipulation, from knockout to point mutation, in relevant cell and animal models. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such discoveries.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of skeletal muscle tissue growth research.
Frequently Asked Questions About negative regulation of skeletal muscle tissue growth
What is GO:0048632?
GO:0048632 is the Gene Ontology term for negative regulation of skeletal muscle tissue growth, defined as any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle growth.
What genes are involved in negative regulation of skeletal muscle growth?
Key genes include MSTN (myostatin), ACVR2B, SMAD2/3, FOXO1/3, FBXO32 (atrogin-1), TRIM63 (MuRF1), and FST (follistatin).
How does myostatin inhibit muscle growth?
Myostatin binds to ACVR2B, activating SMAD2/3 signaling, which suppresses myogenic factors and upregulates ubiquitin ligases, leading to reduced protein synthesis and increased degradation.
What diseases are associated with negative regulation of skeletal muscle growth?
Cancer cachexia, sarcopenia, muscular dystrophies, and disuse atrophy all involve dysregulated negative regulation of muscle growth.
Can CRISPR be used to study negative regulation of skeletal muscle growth?
Yes, CRISPR knockout, knock-in, and activation models can be used to dissect gene function in muscle cells and animal models.
What is the role of follistatin in muscle growth?
Follistatin is an endogenous antagonist of myostatin; by binding myostatin, it prevents receptor activation and promotes muscle growth.
How is negative regulation of muscle growth measured experimentally?
Common methods include RNA-seq, Western blot for SMAD2/3 phosphorylation, immunofluorescence for myotube size, and muscle strength testing in animal models.
What are the therapeutic implications of targeting myostatin?
Inhibiting myostatin signaling can increase muscle mass and strength, offering potential treatments for sarcopenia, cachexia, and muscular dystrophy.
What is the difference between GO:0048632 and muscle atrophy?
GO:0048632 encompasses all processes that negatively regulate muscle growth, including but not limited to atrophy. Muscle atrophy is a consequence of activated negative regulation.
Which cell models are used to study negative regulation of skeletal muscle growth?
C2C12 myoblasts, primary myoblasts, and human iPSC-derived muscle cells are commonly used, along with CRISPR-engineered derivatives.
Conclusion
GO:0048632, negative regulation of skeletal muscle tissue growth, is a critical biological process that maintains muscle mass homeostasis and prevents excessive growth. Its dysregulation underlies major muscle-wasting conditions such as cancer cachexia and sarcopenia. Myostatin and its downstream signaling components are the best-characterized mediators, but ongoing research continues to uncover new regulators. Advances in CRISPR technology and functional genomics are accelerating the discovery of novel therapeutic targets. EDITGENE provides comprehensive CRISPR services to support researchers in dissecting these mechanisms and developing new treatments.
References
- 1. Fearon K et al.. 2011. Definition and classification of cancer cachexia: an international consensus.. Lancet Oncol 12(5):489-95 PMID: 21296615
- 2. Stefanakis K et al.. 2024. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.. Metabolism 161:156057 PMID: 39481534
- 3. Schiaffino S et al.. 2013. Mechanisms regulating skeletal muscle growth and atrophy.. FEBS J 280(17):4294-314 PMID: 23517348
- 4. Lee SJ. 2023. Myostatin: A Skeletal Muscle Chalone.. Annu Rev Physiol 85:269-291 PMID: 36266260
- 5. McPherron AC et al.. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.. Nature 387(6628):83-90 PMID: 9139826
- 6. Tipton KD et al.. 2001. Exercise, protein metabolism, and muscle growth.. Int J Sport Nutr Exerc Metab 11(1):109-32 PMID: 11255140
- 7. Sharma M et al.. 2015. Myostatin: expanding horizons.. IUBMB Life 67(8):589-600 PMID: 26305594
- 8. Zádor E. 2024. Characterization of Skeletal Muscle Regeneration Revealed a Novel Growth Network Induced by Molecular Acupuncture-like Transfection.. Biomolecules 14(3) PMID: 38540781
